CTI BioPharma Corp  

(Public, NASDAQ:CTIC)   Watch this stock  
Find more results for CTIC
0.370
-0.033 (-8.10%)
Jun 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.36 - 0.38
52 week 0.25 - 2.31
Open 0.36
Vol / Avg. 20.50M/948,397.00
Mkt cap 99.04M
P/E     -
Div/yield     -
EPS -0.49
Shares 282.93M
Beta 1.27
Inst. own 39%
Aug 4, 2016
Q2 2016 CTi Biopharma Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 10, 2016
Q1 2016 CTi Biopharma Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 8.20% -749.34%
Operating margin 11.31% -723.91%
EBITD margin - -717.71%
Return on average assets 8.96% -102.13%
Return on average equity 23.78% -261.49%
Employees 149 -
CDP Score - -

Address

3101 Western Ave Ste 600
SEATTLE, WA 98121-3047
United States - Map
+1-206-2827100 (Phone)
+1-206-2846206 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

Officers and directors

Phillip M. Nudelman Ph.D. Independent Chairman of the Board
Age: 79
Bio & Compensation  - Reuters
James A. Bianco M.D. President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Louis A. Bianco Executive Vice President, Finance and Administration, and Chief Governance Officer
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jack W. Singer M.D. Interim Chief Medical Officer, Executive Vice President, Global Medical Affairs and Translational Medicine, and Chief Compliance Officer.
Age: 72
Bio & Compensation  - Reuters
Matthew J. Plunkett Ph.D. Executive Vice President, Corporate Development
Age: 43
Bio & Compensation  - Reuters
Bruce J. Seeley Executive Vice President and Chief Commercial Officer
Age: 51
Bio & Compensation  - Reuters
Nancy L. Boman Ph.D. Senior Vice President of Clinical Development and Regulatory Affairs
Bio & Compensation  - Reuters
Monique M. Greer Senior Vice President of Corporate Communications and Investor Relations
Age: 48
Bio & Compensation  - Reuters
Matthew Perry Director
Bio & Compensation  - Reuters
Richard L. Love Independent Director
Age: 72
Bio & Compensation  - Reuters